Abstract
Both Alzheimer’s disease (AD) and Type 2 diabetes mellitus (T2DM) share the presence of systemic and neuro-inflammation, enhanced production and accumulation of β -amyloid peptide and abnormal levels of the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Altered levels of AChE and BuChE both in AD as well as in T2DM imply that those two enzymes may be playing a pivotal role in the pathogenesis of the two disorders. AD and T2DM are both characterized by elevated levels of AChE and BuChE in the plasma. On the other hand, in AD the brain levels of AChE go down while those of BuChE go up, resulting in deregulation in balance between AChE and BuChE. This imbalance and change in the AChE/BuChE ratio causes cholinergic deficit in the brain, i.e. deficiency in the brain neurotransmitter acetylcholine. With better understanding of the inter-relationship of AChE and BuChE levels in normality as well as abnormality, AD and T2DM can be effectively treated. Thus, general cholinesterase inhibitors that inhibit both AChE and BuChE as well as highly selective BuChE inhibitors may have potential therapeutic benefits in the treatment of AD and other related dementias.
Keywords: Acetylcholinesterase, Alzheimer's disease, butyrylcholinesterase, cholinergic deficit, cholinesterase inhibitors, type 2 diabetes mellitus.
CNS & Neurological Disorders - Drug Targets
Title:Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus
Volume: 13 Issue: 8
Author(s): Gohar Mushtaq, Nigel H. Greig, Jalaluddin A. Khan and Mohammad A. Kamal
Affiliation:
Keywords: Acetylcholinesterase, Alzheimer's disease, butyrylcholinesterase, cholinergic deficit, cholinesterase inhibitors, type 2 diabetes mellitus.
Abstract: Both Alzheimer’s disease (AD) and Type 2 diabetes mellitus (T2DM) share the presence of systemic and neuro-inflammation, enhanced production and accumulation of β -amyloid peptide and abnormal levels of the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). Altered levels of AChE and BuChE both in AD as well as in T2DM imply that those two enzymes may be playing a pivotal role in the pathogenesis of the two disorders. AD and T2DM are both characterized by elevated levels of AChE and BuChE in the plasma. On the other hand, in AD the brain levels of AChE go down while those of BuChE go up, resulting in deregulation in balance between AChE and BuChE. This imbalance and change in the AChE/BuChE ratio causes cholinergic deficit in the brain, i.e. deficiency in the brain neurotransmitter acetylcholine. With better understanding of the inter-relationship of AChE and BuChE levels in normality as well as abnormality, AD and T2DM can be effectively treated. Thus, general cholinesterase inhibitors that inhibit both AChE and BuChE as well as highly selective BuChE inhibitors may have potential therapeutic benefits in the treatment of AD and other related dementias.
Export Options
About this article
Cite this article as:
Mushtaq Gohar, Greig H. Nigel, Khan A. Jalaluddin and Kamal A. Mohammad, Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus, CNS & Neurological Disorders - Drug Targets 2014; 13 (8) . https://dx.doi.org/10.2174/1871527313666141023141545
DOI https://dx.doi.org/10.2174/1871527313666141023141545 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Magnesium and Anaesthesia
Current Drug Targets Transition of Growth Hormone Treatment: Adolescence to Adulthood
Current Pediatric Reviews Effects of Mindfulness on Diabetes Mellitus: Rationale and Overview
Current Diabetes Reviews Ethiopathogenesis, Diagnosis and Prevention of Vascular Calcification in End Stage Renal Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents The Possible Hypoglycemic Mechanisms of Echinochrome
Current Diabetes Reviews Natural Products as Farnesoid X Receptor (FXR) Agonists: Their Interactions with FXR Ligand Binding Region
Mini-Reviews in Organic Chemistry Is There any Correlation Between Diabetic Retinopathy and Risk of Cardiovascular Disease?
Current Diabetes Reviews Insulin Action on the Human Placental Endothelium in Normal and Diabetic Pregnancy
Current Vascular Pharmacology Calpains: Attractive Targets for the Development of Synthetic Inhibitors
Current Topics in Medicinal Chemistry Targeting Platelet G-Protein Coupled Receptors (GPCRs): Looking Beyond Conventional GPCR Antagonism
Current Vascular Pharmacology Statins and epilepsy: preclinical studies, clinical trials and statin-anticonvulsant drug interactions
Current Drug Targets New Immunosuppressants: Immunosuppression and Immunomodulation
Medicinal Chemistry Reviews - Online (Discontinued) Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Current Diabetes Reviews Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Benign Prostatic Hyperplasia and Clinical Prostate Cancer - Two New Components of the Metabolic Syndrome
Current Hypertension Reviews Pharmacological Treatment of Obesity: Current Standards and Future Perspectives
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Insights into the Platelet Releasate
Current Pharmaceutical Design Management of Acute and Chronic Open Wounds: The Importance of Moist Environment in Optimal Wound Healing
Current Pharmaceutical Biotechnology Obesity: A New Pathology to Pay Attention to in Young People
Current Pharmaceutical Design